Objectives: To determine whether prolonged intensive disease-modifying antirheumatic drug (DMARD) treatment (PRINT) leads to high remission and low relapse rates in patients with severe rheumatoid arthritis (RA).
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovitis, cartilage damage, and bone erosion, leading to deformity and disability. Clinical remission or low disease activity (LDA) is the recommended treatment target in patients with RA. [1] Conventional disease-modifying antirheumatic drugs (DMARDs) remain the core medications employed in daily practice in many parts of the world. [2] Intensive treatment using combinations of DMARDs is proposed to be superior to routine step-up DMARD treatment. [3] [4] [5] [6] However, in clinical practice, after patients achieve the treatment target, DMARDs are often tapered. [1, 7] It has been reported that the risk of flare is higher in patients tapering DMARDs early than those continuing therapy. [8, 9] Few studies have directly addressed the optimal approach to tapering. We hypothesized that prolonged intensive DMARD therapy will result in a high proportion of patients achieving remission and subsequently few patients relapsing upon DMARD tapering.
Methods

Trial design and participants
We performed a controlled randomized, single-blinded, parallel treatment trial of tapering protocols after initial intensive DMARD therapy. Nine hospitals in China collaborated and enrolled patients from July 2009 to June 2010. Follow-up was ended in March 2012. Key inclusion criteria were as follows: RA according to the 1987 revised American College of Rheumatology criteria [10] ; disease activity score (28 joints) (DAS28) > 5.1 and age >18 years. Key exclusion criteria were previous use of prednisone >10 mg orally, chronic liver disease, cancer, excessive alcohol use, pregnancy (intended), or laboratory abnormalities: leucopenia (<4.0 Â 10 9 /L), thrombocytopenia (<100 Â 10 9 /L), elevated aspartate aminotransferase, alanine aminotransferase, and creatinine level.
The study was approved by Peking University People's Hospital's ethics committee. All patients gave written informed consent. This trial was registered in World Health Organization's International Clinical Trial Registry Platform with www.chictr. org (No. ChiCTR-TRC-09000469).
Randomization
Patients who achieved LDA during an open-label induction period were eligible for the step-down maintenance stage, and were randomly assigned by sealed opaque envelope containing computer-generated random allocations in a 1:1 ratio to 1 of 2 treatment groups. The statistician who generated the randomization sequence was not otherwise involved in the trial.
Interventions
There were 2 phases in the study. In phase 1, enrolled patients received DMARDs treatment comprising a combination of methotrexate (MTX), leflunomide (LEF), and hydroxychloroquine (HCQ). The starting dose of oral MTX was 7.5 mg/wk that could be increased to a maximum of 20 mg/wk. LEF (10-20 mg/d per rheumatologists' discretion) and HCQ (400 mg/d) were administrated in combination with MTX. Adverse events (AEs) and serious AEs were recorded throughout the study. Folic acid was administered to every patient (5 mg/wk, 1 single dose). Use of nonsteroidal anti-inflammatory drugs was allowed and the dose could be changed in the study. Intra-articular or intramuscular injection of glucocorticoids was allowed only once (no more than 40 mg Triamcinolone Acetonide or its equivalent) at the beginning of the study. Oral glucocorticoids (prednisone 10 mg/d) were allowed but were tapered to discontinuation before entering the step-down maintenance period. Disease activity was assessed every 12 weeks. Patients who achieved a DAS28 3.2 entered the maintenance period.
In phase 2, patients who achieved a DAS28 3.2 were randomized to 1 of 2 step-down maintenance regimens: LEF monotreatment group (10 mg/d) or LEF (10 mg/d) plus HCQ (400 mg/d) group. Disease activity was assessed every 12 weeks. Remission was defined as DAS28 2.6. [11] Relapse of disease activity was defined as a DAS28 increase ≥ 0.6 from prior assessment. [12] Patients were followed for up to 48 weeks after randomization.
Outcome assessment
The primary endpoint was good European League Against Rheumatism (EULAR) response (i.e., a resulting DAS28 (erythrocyte sedimentation rate [ESR]) < 3.2 and a decrease of DAS28 by at least 1.2) [13] during the prolonged intensive treatment. The secondary endpoint was the disease retention (maintenance of good EULAR response) rate during step-down maintenance treatment. Clinically relevant predictive factors for good EULAR response in the prolonged intensive treatment period and predictive factors for disease flare in the randomized step-down maintenance period were assessed. Health assessment questionnaire disability index (HAQ, which had been translated and validated for the enrolled patients), swollen and tender joint counts (28 joints), concentration of C-reactive protein, erythrocyte sedimentation rate, physician and patient global assessments (0-10 cm visual analog scales), and patient assessed pain and fatigue (0-10 cm visual analog scales) were measured. Rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies were performed by enzyme-linked immunosorbent assay twice at entry of the intensive and maintenance treatment phases, respectively. Extra-articular features were acquired, including rheumatoid nodules, vasculitis, secondary Sjogren syndrome, interstitial lung disease, and other extra-articular manifestations associated with RA.
Statistical analysis
A sample size of 344 patients was estimated for the intensive treatment period with the assumption that 80% of patients would achieve LDA or remission at the end of intensive treatment stage (on the basis of the TICORA trial). [14] A sample size of 110 Li et al. Medicine (2016) 95:28 Medicine patients per maintenance treatment group was calculated to have 90% power to detect a 15% difference between the 2 groups with an a level of 0.05. In the intensive treatment period, the intention-to-treat population included all patients who received at least 1 dose of study drug. Patients who were lost to follow-up, or withdrew from the trial were designated as nonresponders. In the randomized maintenance treatment period, the intention-to-treat population was made up of patients who had randomized and received at least 1 dose of assigned maintenance treatment. The safety population included all patients given at least 1 dose of study drug.
Descriptive statistics, nonparametric test, and x 2 test were used as appropriate. Variables that were significant at P < 0.20 on the univariate analysis were entered into the multivariate model. Backward multivariate logistic regression analyses were conducted for the baseline predictors of good EULAR response at 12 weeks of the intensive treatment. Cox regression was performed to analyze the predictors for flare during the maintenance period. A 2-tailed P value < 0.05 was considered significant. Analyses were performed using the SPSS/PC program (version 16.0; Chicago, IL).
Results
Study population
Three hundred forty-six patients were recruited ( Fig. 1) , and their baseline metrics are shown in Table 1 . The mean age of patients was 48.7 years with a mean duration of disease of 6.13 years. There were 35.3% (122/346) patients who did not received DMARDs treatment previously. The prevalence of patients who were receiving 1 or 2 DMARDs treatment at the enrollment was 16 .8% (58/346). Furthermore, 16.2% (56/346) patients received oral glucocorticoids (prednisone 10 mg/d). The mean DAS28 at baseline was 6.17.
Response in intensive DMARDs treatment
In phase 1, the proportion of patients achieving a good EULAR response rose from 18.7% (64/343) to 36.9% (128/344) and 54.1% (187/346) at 12, 24, and 36 weeks. The total proportion 
Maintenance of LDA or remission in maintenance treatment
In phase 2, 176 patients achieving LDA or remission randomly entered into the step-down maintenance treatment phase of the study. By 48 weeks, 36.9% (65/176) patients maintained LDA or remission. Furthermore, we explored the impact of maintenance treatment regimens, disease, and functional activity on the maintenance of LDA.
In the LEF group, 36.8% (32/87) patients remained in LDA. In the LEF + HCQ group, the proportion of patients remaining LDA was 37.1% (33/89). For intent-to-treatment population, there was no difference in disease activity maintenance rate between the 2 groups (data not shown, P = 0.53).
Patients achieving remission at initiation of the maintenance phase had a significantly higher retention rate of disease activity, compared with those achieving LDA by the point of taper (P = 0.046). Similarly, a higher retention rate of the disease activity state was showed in patients with a low HAQ ( 0.5), in comparison with those with HAQ > 0.5 (P = 0.01) at the start of phase 2. Additionally, patients achieving both remission and low HAQ had the highest retention rate during the maintenance period, compared with patients achieving only LDA or high HAQ (compared with 2.6 < DAS28 3.2/LDA > 0.5, P = 0.02; compared with DAS28 2.6/LDA > 0.5, P = 0.04, Fig. 3 ).
Predictor analysis
To identify baseline factors that predicted the early response for the intensive DMARD treatment, we evaluated clinical variables in patients achieving or failing to achieve a good EULAR response at 12 weeks. Those with a good EULAR response were younger (43.8 ± 13.6 years vs 47.9 ± 12.7 years, P = 0.03), and had a lower baseline DAS28 score and ESR (DAS28: 5.98 ± 0.68 vs 6.32 ± 0.92, P = 0.001; ESR: 43.08 ± 29.43 mm/h vs 56.63 ± 30.14 mm/h, P = 0.002). Five variables with statistical significance at P < 0.20 in the bivariate analysis were entered into the logistic regression analysis: age, number of tender joint, DAS28, HCQ, and ESR. Age and ESR were independent predictors for the good EULAR response of the intensive treatment arm (P = 0.03 and P = 0.003, Table 2 ).
Univariate analysis of potential variables associated with a flare showed that achieving remission (DAS28 2.6) (P = 0.07), pain score (P = 0.05), physician global health (P = 0.02), fatigue score (P = 0.08), patient global assessment (P = 0.09), high HAQ (>0.5) (P = 0.02), and C-reactive protein (P = 0.02) at the entry of maintenance treatment were associated with disease relapse. Cox regression analysis demonstrated that high HAQ (OR: 2.16, 95% CI: 1.08-4.32, P = 0.03) was an independent risk factor for the flare (Table 3) . LDA or remission maintenance rate was not associated with the duration of prolonged intensive treatment, the maintenance treatment regimens, sex, age, and disease duration (data not shown). There were significantly higher disease retention rate in patients achieving remission (DAS28 2.6) than those achieving LDA (2.6 < DAS28 3.2) (P = 0.046). (B) Retention rate in patients with different functional activity. There were significantly higher disease retention rate in patients having low HAQ ( 0.5) than those having HAQ > 0.5 (P = 0.01). (C) Retention rate in patients with different DAS28 and HAQ. It had been shown that patients achieving both remission and low HAQ had the highest disease retention rate during the maintenance period (DAS28 2.6/HAQ 0.5 vs 2.6 < DAS28 3.2/HAQ > 0.5, P = 0.02; vs DAS28 2.6/HAQ > 0.5, P = 0.04; vs 2.6 < DAS28 3.2/HAQ 0.5, P = 0.25, respectively). DAS28 = disease activity score (28 joints), HAQ = health assessment questionnaire, LDA = low disease activity.
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Adverse events
One hundred fifty AEs were reported in 346 patients representing a prevalence of 43.4% (150/346). The most common AEs were elevated transaminases (14.16%), and then upper abdominal illness (13.01%). Twenty-four patients discontinued the study because of the occurrence of AEs. Eight patients hospitalized for AEs: 2 upper abdominal illnesses, 2 pneumonia, 1 elevated transaminase, 1 pulmonary tuberculosis, 1 pneumatothorax, and 1 cerebral hemorrhage (Table 4 ).
Discussion
In 2010, Treat-to-Target (T2T) expert committee recommended that until the desired treatment target was reached, drug treatment should be adjusted. [1] New EULAR recommendation published in 2013 put forward to the idea the treatment target (remission or at least LDA) should be attained within 6 months and not necessarily within 3 months. [15] However, it is not known whether remission rate will increase if the intensive DMARDs therapy is prolonged. In this study, we found high response rate of RA with prolonged intensive DMARDs therapy. The proportion of patients with good EULAR response increased with time without shifting the treatment. There was around 18% increment of good response rate at 36 weeks. The result suggested that prolonged intensive treatment could be continued and steered though the treat goal was not reached at 6 months.
Several studies have analyzed the role of baseline characteristics as predictors of response, such as HAQ, disease duration, Table 3 Potential variables associated with a flare at the entry of maintenance treatment.
Univariate analysis Multivariate analysis
Variables OR (95% CI) P OR (95% CI) P Anti-CCP = anticyclic citrullinated peptide, CI = confidence interval, CRP = C-reactive protein, DAS28 = disease activity score (28 joints), ESR = erythrocyte sedimentation rate, EULAR = European League Against Rheumatism, HAQ = health assessment questionnaire, MGA = medical global assessment, OR = odds ratio, PGA = patient global assessment, RF = rheumatoid factor, SD = standard deviation, SJC = swollen joint count, TJC = tender joint count, VAS = visual analog scale. *
Significant.
Li et al. Medicine (2016) 95:28 www.md-journal.com and baseline disease activity. [16, 17] Sex and age have also been related to the treatment response. [18] [19] [20] In our study, we found that age and ESR were the predictors for the outcome of intensive treatment, which was similar with the previous reports.
[ 20] It seemed that young patients with low level of ESR were prone to respond to intensive treatment. Predicting clinical outcomes based upon baseline factors would be useful to help select the optimal management of RA.
Our study showed that patients achieving DAS28 remission and low functional activity (HAQ) had highest retention of their disease state and by corollary lowest relapse rates. HAQ was an independent predictor for disease relapse. Thus better control of disease activity (both clinical and functional) was important for sustaining the target during intensive treatment. Studies predicting flare of RA are rare. Scirè et al [21] showed that ultrasound power Doppler (PD)-positive synovial hypertrophy, even in a single joint, was the main predictor of relapse within 6 months. Saleem et al [22] reported that baseline PD activity, HAQ, and DAS28 predicted the flare after remission. Flare was associated with worse clinical and functional outcomes. Our results further confirmed the important impact of DAS28 and HAQ on the maintenance of the treatment target.
In this study, unique conventional DMARDs therapy using MTX in combination with LEF and HCQ was given to severely active RA patients. This combination therapy was thought to be toxic and rarely used in current clinical trials. In our study, good effect and safety of the triple intensive treatment were found during 36th week. MTX, as an anchor drug in RA, was the most common drug in RA treatment. In addition, a number of studies have shown that LEF has comparable efficacy to MTX. [23] [24] [25] [26] In maintenance period, MTX and prednisone were withdrawn. We found that there was no advantage on tapering to combination rather than monotherapy, suggesting that LEF is a good maintenance treatment as single treatment. Though there were also some weakness of the study, such as the open label design and significant dropout, the study evaluated the induction and maintenance of remission of prolonged intensive DMARDs treatment at the first time.
In conclusion, the prolonged intensive DMARDs treatment was an effective treatment strategy for active RA, and a high remission could be continued and steered though the treat goal was not reached at 6 months. Higher remission and a lower HAQ lead to less flare when tapering the DMARDs. Twenty-four adverse events were followed by withdrawal of study drugs: upper abdominal illness 7, rash 4, elevated transaminase 3, pneumonia 2, herpes zoster 1, leukopenia 1, elevated creatine kinase 1, dizziness 1, alopecia 1, pneumatothorax 1, cerebral hemorrhage 1, and pulmonary tuberculosis 1. Eight severe adverse events causing hospitalization were upper abdominal illness 2, pneumonia 2, elevated transaminase 1, pulmonary tuberculosis 1, pneumatothorax, 1, and cerebral hemorrhage 1. * Twelve infective events were upper respiratory tract infection 4, pneumonia 3, herpes zoster 2, urinary infection 1, acute bronchitis 1, and pulmonary tuberculosis 1.
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